• AZD3463: High-Affinity ALK/IGF1R Inhibitor for Neuroblastoma

  2026-05-06

  AZD3463 is a potent, orally bioavailable ALK/IGF1R inhibitor with nanomolar affinity that suppresses neuroblastoma cell proliferation and induces apoptosis through PI3K/AKT/mTOR pathway inhibition. It exhibits activity against both wild-type and mutant ALK, and enhances the efficacy of chemotherapeutic agents in vitro and in vivo. This product dossier provides a structured analysis of the evidence, practical workflow parameters, and key boundaries for translational research.

• Sumatriptan Succinate: Experimental Workflows for Migraine R

  2026-05-05

  Sumatriptan Succinate stands out as a robust 5-HT1 receptor agonist for dissecting serotonergic and neuroinflammatory pathways. This article details optimized research protocols, advanced applications, and troubleshooting strategies that empower translational and bench scientists alike.

• Homoharringtonine Rapidly Clears SARS-CoV-2 in Preclinical a

  2026-05-05

  This study demonstrates that homoharringtonine, a cytotoxic alkaloid and protein synthesis inhibitor, can eliminate SARS-CoV-2 from the upper respiratory tract in both animal models and human subjects within days. The findings support its potential as a first-line antiviral defense in future coronavirus epidemics and offer detailed protocol insights for translational research.

• TSPAN18 Protects STIM1 to Drive Prostate Cancer Bone Metasta

  2026-05-04

  Zhou et al. (2023) uncover a novel mechanism by which TSPAN18 sustains STIM1 protein stability, thereby promoting calcium influx and bone metastasis in prostate cancer. Their findings highlight TSPAN18 as a potential therapeutic target for impeding metastatic progression via the STIM1-calcium signaling axis.

• WZ4003: Selective NUAK1/2 Inhibitor for Cancer and Tau Resea

  2026-05-04

  WZ4003 is a highly selective NUAK1/2 inhibitor widely used in cancer and neurodegenerative disease research. It exhibits potent inhibition of NUAK1 (IC50 = 20 nM) and NUAK2 (IC50 = 100 nM), impairs cell migration and proliferation, and reduces tau phosphorylation linked to Alzheimer’s pathology.

• Phenothiazines Boost Macrophage Antibacterial Activity via R

  2026-05-03

  This study demonstrates that phenothiazines, notably perphenazine, enhance macrophage-mediated antibacterial defense by inducing reactive oxygen species (ROS) accumulation and autophagy. These findings clarify a host-directed mechanism for phenothiazines and open new avenues for antibacterial research beyond traditional antibiotic strategies.

• Genetic Engineering to Overcome Immune-Cold Solid Tumor Barr

  2026-05-02

  He et al. (2025) introduce a tumor-specific plasmid vector that drives local expression of αCD3 and LIGHT, synergistically enhancing T cell infiltration and antitumor activity in immune-cold solid tumors. This strategy potentiates the efficacy of checkpoint inhibitors and CAR-T cells with minimal systemic toxicity, offering a promising advance for solid tumor immunotherapy.

• Rosiglitazone (Brl-49653): Strategic Leverage in Translation

  2026-05-01

  This thought-leadership article unpacks the multi-dimensional role of Rosiglitazone (Brl-49653), a synthetic thiazolidinedione, as both a mechanistic probe and translational tool in metabolic research. Grounded in recent functional genomics findings, especially the partial rescue of PPARG R212W mutation by Rosiglitazone, it guides researchers through biological rationale, protocol best practices, and benchmarks for experimental use. The piece uniquely bridges insights from rare lipodystrophy to mainstream diabetes research, highlights APExBIO’s product excellence, and positions Rosiglitazone within an evolving translational landscape.

• Verteporfin: Mechanistic Versatility for Translational Break

  2026-05-01

  Explore how Verteporfin (CL 318952) empowers translational researchers with dual functionality—precision photodynamic therapy and light-independent autophagy inhibition. This article synthesizes mechanistic insight, validated protocols, and strategic guidance, referencing recent senolytic discoveries and advancing the conversation on targeted cell clearance.

• Scenario-Driven Solutions with G007-LK Tankyrase 1/2 Inhibit

  2026-04-30

  This article addresses real laboratory scenarios involving cell viability, proliferation, and pathway modulation, showing how G007-LK tankyrase 1/2 inhibitor (SKU B5830) delivers reliable, reproducible results. Researchers gain actionable guidance for robust Wnt/β-catenin and Hippo pathway interrogation, grounded in peer-reviewed data and best practices.

• YAP-TEAD Orchestrates Super-Enhancer Networks in Surface Ect

  2026-04-30

  Wang et al. (2026) illuminate how the YAP-TEAD complex regulates super-enhancer landscapes to direct early surface ectoderm commitment from pluripotent stem cells. Their integration of 3D genomics, chromatin profiling, and functional perturbation unveils new mechanistic insight into lineage specification and regenerative potential.

• EPZ5676: Redefining DOT1L Inhibition for Advanced Leukemia R

  2026-04-29

  Explore EPZ5676, a potent and selective DOT1L inhibitor, with a focus on its unparalleled selectivity, innovative assay guidance, and translational value for MLL-rearranged leukemia treatment. This article delivers deeper mechanistic insights and unique workflow strategies for epigenetic research.

• Verteporfin (CL 318952): Mechanisms and Evidence for Photody

  2026-04-29

  Verteporfin is a clinically validated, second-generation photosensitizer, primarily used in photodynamic therapy for ocular neovascularization. It exhibits dual mechanisms: light-activated vascular occlusion and autophagy inhibition via p62 targeting. This article provides atomic, verifiable facts and best-practice benchmarks for research and clinical translation.

• Catalpol’s Anticancer Mechanisms: Insights from Recent Revie

  2026-04-28

  A recent comprehensive review consolidates preclinical evidence that catalpol, a natural iridoid glycoside, exerts anticancer activity through multi-pathway modulation, including apoptosis induction, signaling pathway regulation, and inhibition of metastasis. These findings highlight catalpol’s potential as an adjunct in cancer therapy and underscore the need for translational research to bridge promising laboratory results into clinical studies.

• Optimizing hiPSC-Derived Platelet Differentiation with Small

  2026-04-28

  This study presents an optimized protocol for generating functional platelets from human induced pluripotent stem cells (hiPSCs) by increasing embryoid body input, refining media, and strategically substituting cytokines with small molecules. The approach improves platelet yield, accelerates differentiation, and markedly reduces production costs, offering scalable potential for cell therapy and gene editing applications.

16314 records 1/1088 page Next 12345 下5页 Last page